The review by researchers at Anglia Ruskin University in the UK looked at 30 published studies conducted in cell cultures and ...
GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...
Stocktwits on MSN
A key FDA verdict on this firm’s Alzheimer’s drug is scheduled this week – stock has already gained nearly 15% in a month
Axsome’s supplemental new drug application for AXS-05 was accepted by the FDA last December. ・The drug could be used in about 76% of Alzheimer’s patients who experience agitation, including symptoms ...
A major review challenges a long-standing strategy in Alzheimer’s research, suggesting that removing a hallmark brain protein ...
Critics say the meta-analysis provides an inaccurate picture of anti-amyloid medications. Two of them have FDA approval.
Alzheimer’s “wonder drugs” do not work, scientists have found in a study that overturns decades of research into the disease.
Biogen Inc.’s first-quarter sales and profit beat expectations, a sign that the company’s Alzheimer’s drug and cost cuts are ...
A few common medications, like statins or drugs to treat high blood pressure, appear to help lower the risk for dementia. But ...
The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, ...
A new study has found comprehensive evidence that "weight-loss" GLP-1 receptor agonists such as semaglutide are effective in ...
Anti-amyloid drugs may not have a clinically meaningful effect in the treatment of Alzheimer's disease, a new review says. So ...
Anti-amyloid drugs likely provide no "clinically meaningful" effects for people with Alzheimer's, the authors concluded.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results